Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Justin C. Chia & P. Régine Mydlarski. (2017) Dermatologic uses of omalizumab. Journal of Dermatological Treatment 28:4, pages 332-337.
Read now
Read now
Nancy Gupta, Arun Aggarwal, Rahul Gupta, Sachin Sule & David C. Wolf. (2015) The management of eosinophilic gastroenteritis. Scandinavian Journal of Gastroenterology 50:11, pages 1309-1314.
Read now
Read now
Cristoforo Incorvaia, Marina Mauro, Marina Russello, Chiara Formigoni, Gian Galeazzo Riario-Sforza & Erminia Ridolo. (2014) Omalizumab, an anti-immunoglobulin E antibody: state of the art. Drug Design, Development and Therapy 8, pages 197-207.
Read now
Read now
Amelia Licari, Giorgio Ciprandi, Alessia Marseglia, Riccardo Castagnoli, Salvatore Barberi, Silvia Caimmi & Gian Luigi Marseglia. (2014) Current recommendations and emerging options for the treatment of allergic rhinitis. Expert Review of Clinical Immunology 10:10, pages 1337-1347.
Read now
Read now
Salvatore Chirumbolo. (2014) Immunotherapy in allergy and cellular tests. Human Vaccines & Immunotherapeutics 10:6, pages 1595-1610.
Read now
Read now
Articles from other publishers (36)
Arianna Giannetti, Alessandro Ruggi, Giampaolo Ricci, Giuliana Giannì & Carlo Caffarelli. (2023) Natural History of Hazelnut Allergy and Current Approach to Its Diagnosis and Treatment. Children 10:3, pages 585.
Crossref
Crossref
Soyang Ella Kim, Victoria Nowak, Ana Quartilho, Frank Larkin, Melanie Hingorani, Stephen Tuft & Annegret Dahlmann-Noor. (2020) Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years. Cochrane Database of Systematic Reviews 2020:10.
Crossref
Crossref
Javier Fernandez, María Ruano-Zaragoza & Natalia Blanca-Lopez. (2020) Omalizumab and other biologics in drug desensitization. Current Opinion in Allergy & Clinical Immunology Publish Ahead of Print.
Crossref
Crossref
Soyang Ella Kim, Ana Quartilho, Frank Larkin, Melanie Hingorani, Stephen Tuft & Annegret Dahlmann-Noor. (2019) Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Zhen Zhang, Zelang Cai, Yibo Hou, Jiayun Hu, Yongshen He, Jiajie Chen & Kunmei Ji. (2019) Enhanced sensitivity of capture IgE‑ELISA based on a recombinant Der f 1/2 fusion protein for the detection of IgE antibodies targeting house dust mite allergens. Molecular Medicine Reports.
Crossref
Crossref
C. C. Loureiro, L. Amaral, J. A. Ferreira, R. Lima, C. Pardal, I. Fernandes, L. Semedo & A. Arrobas. (2018) Omalizumab for Severe Asthma: Beyond Allergic Asthma. BioMed Research International 2018, pages 1-10.
Crossref
Crossref
Maria Maddalena Sirufo, Massimo De Martinis & Lia Ginaldi. (2018) Omalizumab an effective and safe alternative therapy in severe refractory atopic dermatitis. Medicine 97:24, pages e10897.
Crossref
Crossref
J. A. Dantzer & R. A. Wood. (2018) The use of omalizumab in allergen immunotherapy. Clinical & Experimental Allergy 48:3, pages 232-240.
Crossref
Crossref
M. Ferrer & R. Madamba. (2017) Biologics in chronic urticaria. Allergologia et Immunopathologia 45, pages 41-44.
Crossref
Crossref
M. Ollé‐Monge, M.J. Cruz, S. Gomez‐Ollés, I. Ojanguren, J. Vanoirbeek & X. Muñoz. (2017) Effect of anti‐IgE in occupational asthma caused by exposure to low molecular weight agents. Allergy 72:11, pages 1720-1727.
Crossref
Crossref
Christian Domingo, Xavier Pomares, Albert Navarro, Núria Rudi, Ana Sogo, Ignacio Dávila & Rosa Mirapeix. (2017) Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study. International Journal of Molecular Sciences 18:3, pages 521.
Crossref
Crossref
Piotr Kuna, Dariusz Jurkiewicz, Magdalena M. Czarnecka-Operacz, Rafał Pawliczak, Jarosław Woroń, Marcin Moniuszko & Andrzej Emeryk. (2017) The role and choice criteria of antihistamines in allergy management – Expert opinion. Alergologia Polska - Polish Journal of Allergology 4:1, pages 7-19.
Crossref
Crossref
Odelya E. Pagovich, Bo Wang, Maria J. Chiuchiolo, Stephen M. Kaminsky, Dolan Sondhi, Clarisse L. Jose, Christina C. Price, Sarah F. Brooks, Jason G. Mezey & Ronald G. Crystal. (2016) Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy. Journal of Allergy and Clinical Immunology 138:6, pages 1652-1662.e7.
Crossref
Crossref
Sean S. Liour, Andrew Tom, Yueh‐Hsuan Chan & Tse Wen Chang. (2016) Treating IgE‐mediated diseases via targeting IgE‐expressing B cells using an anti‐CεmX antibody. Pediatric Allergy and Immunology 27:5, pages 446-451.
Crossref
Crossref
Eusebi Chiner, Estrella Fernández-Fabrellas, Pedro Landete, Laura Novella, Mercedes Ramón, José Norberto Sancho-Chust, Cristina Senent & Javier Berraondo. (2016) Comparación de costes y resultados clínicos entre la administración hospitalaria o ambulatoria de omalizumab, en pacientes con asma grave no controlada. Archivos de Bronconeumología 52:4, pages 211-216.
Crossref
Crossref
Eusebi Chiner, Estrella Fernández-Fabrellas, Pedro Landete, Laura Novella, Mercedes Ramón, José Norberto Sancho-Chust, Cristina Senent & Javier Berraondo. (2016) Comparison of Costs and Clinical Outcomes Between Hospital and Outpatient Administration of Omalizumab in Patients With Severe Uncontrolled Asthma. Archivos de Bronconeumología (English Edition) 52:4, pages 211-216.
Crossref
Crossref
David El-Qutob. (2015) Off-Label Uses of Omalizumab. Clinical Reviews in Allergy & Immunology 50:1, pages 84-96.
Crossref
Crossref
Eli Magen & Tinatin Chikovani. (2016) Possible therapeutic role of IgE blockade in irritable bowel syndrome. World Journal of Gastroenterology 22:43, pages 9451.
Crossref
Crossref
Arnau Navinés-Ferrer, Eva Serrano-Candelas, Gustavo-J Molina-Molina & Margarita Martín. (2016) IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. Journal of Immunology Research 2016, pages 1-12.
Crossref
Crossref
E. Serrano-Candelas, R. Martinez-Aranguren, A. Valero, J. Bartra, G. Gastaminza, M. J. Goikoetxea, M. Martín & M. Ferrer. (2016) Comparable actions of omalizumab on mast cells and basophils. Clinical & Experimental Allergy 46:1, pages 92-102.
Crossref
Crossref
Dana Malajian & Emma Guttman-Yassky. (2015) New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 73:2, pages 311-318.
Crossref
Crossref
Bettina Wedi. (2015) Successful Treatment of the Different Urticaria Subtypes. Current Dermatology Reports 4:2, pages 71-76.
Crossref
Crossref
Ibon Eguíluz-Gracia, Teresa Robledo-Echarren, Ricardo Suárez-Fernández, Montserrat Fernández-Rivas & Silvia Sánchez-Ramón. (2015) Omalizumab for the treatment of atopic dermatitis. Clinical Investigation 5:2, pages 121-136.
Crossref
Crossref
Arzu Didem Yalcin. (2015) Advances in Anti-IgE Therapy. BioMed Research International 2015, pages 1-11.
Crossref
Crossref
AD Yalcin. (2014) ANTI-Ige: An Overview. Global Journal of Allergy, pages 003-012.
Crossref
Crossref
Gennaro D’Amato, Anna Stanziola, Alessandro Sanduzzi, Gennaro Liccardi, Antonello Salzillo, Carolina Vitale, Antonio Molino, Alessandro Vatrella & Maria D’Amato. (2014) Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review. Multidisciplinary Respiratory Medicine 9:1.
Crossref
Crossref
Philippe Bégin, Tina Dominguez, Shruti P Wilson, Liane Bacal, Anjuli Mehrotra, Bethany Kausch, Anthony Trela, Morvarid Tavassoli, Elisabeth Hoyte, Gerri O’Riordan, Alanna Blakemore, Scott Seki, Robert G Hamilton & Kari C Nadeau. (2014) Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy, Asthma & Clinical Immunology 10:1.
Crossref
Crossref
Amelia Licari, Alessia Marseglia, Silvia Caimmi, Riccardo Castagnoli, Thomas Foiadelli, Salvatore Barberi & Gian Luigi Marseglia. (2014) Omalizumab in Children. Pediatric Drugs 16:6, pages 491-502.
Crossref
Crossref
Michael P. Makris, Evangelia Papadavid & Torsten Zuberbier. (2014) The use of biologicals in cutaneous allergies – present and future. Current Opinion in Allergy & Clinical Immunology 14:5, pages 409-416.
Crossref
Crossref
Marc Humbert, William Busse, Nicola A. Hanania, Philip J. Lowe, Janice Canvin, Veit J. Erpenbeck & Stephen Holgate. (2014) Omalizumab in Asthma: An Update on Recent Developments. The Journal of Allergy and Clinical Immunology: In Practice 2:5, pages 525-536.e1.
Crossref
Crossref
Jim Fernandez & Cem Akin. (2014) Management of Idiopathic Anaphylaxis: When Is Bone Marrow Examination Essential?. Current Treatment Options in Allergy 1:3, pages 221-231.
Crossref
Crossref
D. Wieczorek, A. Kapp & B. Wedi. (2014) Unverträglichkeit der spezifischen Immuntherapie mit HymenopterengiftIntolerance of specific immunotherapy with Hymenoptera venom. Der Hautarzt 65:9, pages 791-795.
Crossref
Crossref
Tali Czarnowicki, James G. Krueger & Emma Guttman-Yassky. (2014) Skin Barrier and Immune Dysregulation in Atopic Dermatitis: An Evolving Story with Important Clinical Implications. The Journal of Allergy and Clinical Immunology: In Practice 2:4, pages 371-379.
Crossref
Crossref
Mario Cazzola & Andrea Segreti. (2014) Omalizumab: Stepping Outside Our Comfort Zone to Broaden the Number of Those Who Can Benefit. Drugs 74:5, pages 535-537.
Crossref
Crossref
Stephen T Holgate. (2014) New strategies with anti-IgE in allergic diseases. World Allergy Organization Journal 7, pages 17.
Crossref
Crossref
M. Hotze, H. Baurecht, E. Rodr?guez, N. Chapman-Rothe, M. Ollert, R. F?lster-Holst, J. Adamski, T. Illig, J. Ring & S. Weidinger. (2014) Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 69:1, pages 132-135.
Crossref
Crossref